Radboud Translational Medicine

Radboud Translational Medicine (RTM) is a company specializing in the development and production of radiopharmaceuticals. Founded on August 18, 2011, RTM operates a state-of-the-art cyclotron facility that plays a crucial role in advancing nuclear medicine and diagnostics. The company's core technology revolves around a Siemens Eclipse HP cyclotron, which produces radionuclides that are then connected to molecules to create radiopharmaceuticals for medical applications.

RTM's facility spans 1200 square meters and includes three GMP-qualified preparation rooms, quality control laboratories for testing radiopharmaceuticals, logistics areas for distribution, and a radionuclide lab for preclinical preparations and research activities. The company received its GMP certificate from the healthcare Inspectorate in October 2016, enabling it to produce and deliver various radiopharmaceuticals.

The company's product portfolio has expanded over the years. RTM began delivering 18F-FDG to Radboudumc in December 2016 and received a marketing authorization for it in July 2018. Other products include 18F-FDOPA, Ammonia, 18F-PSMA-1007, 89Zr-DFO-Girentuximab, 18F-NaF, 18F-DPA-714, and 18F-FE-PE21-E. In 2018, RTM also started processing QuiremSpheres, handling dispensing and final quality control. The company added a second cyclotron, an IBA Kiube, which became operational in April 2023, enhancing its production capabilities.

RTM's work contributes significantly to the field of nuclear diagnostics, enabling better visualization of disease processes and supporting the development of personalized medicine. The company's radiopharmaceuticals are used in positron emission tomography (PET), which aids in diagnosing and researching various conditions including cancers, Alzheimer's disease, Parkinson's disease, and diabetes.